Use of beta-blockers in congestive heart failure

2003 ◽  
Vol 35 (4) ◽  
pp. 259-266 ◽  
Author(s):  
John A Sallach ◽  
Sidney Goldstein
Author(s):  
Amit Frenkel ◽  
Yoav Bichovsky ◽  
Natan Arotsker ◽  
Limor Besser ◽  
Ben-Zion Joshua ◽  
...  

Background: Beta blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents. However, when thyrotoxicosis is not controlled, heart rate may be difficult to control even with maximal doses of propranolol. This presentation alerts physicians to the possibility of using ivabradine, a selective inhibitor of the sinoatrial pacemaker, for the control of heart rate. Case presentation: We present a 37-year-old woman with thyrotoxicosis and congestive heart failure whose heart rate was not controlled with a maximal dose of beta blockers during a thyroid storm. The addition of ivabradine, a selective inhibitor of the sinoatrial pacemaker, controlled her heart rate within 48 hours. Conclusion: Ivabradine should be considered in patients with thyrotoxicosis, including those with heart failure, in whom beta blockers are insufficient to control heart rate


1998 ◽  
Vol 16 (5) ◽  
pp. 340
Author(s):  
P A Heidenreich ◽  
T T Lee ◽  
B M Massie

2021 ◽  
Author(s):  
Sricharan Bandhakavi ◽  
Zhipeng Liu ◽  
Sunil Karigowda ◽  
Jasmine McCammon ◽  
Farbod Rahmanian ◽  
...  

Objective We recently reported that hypertension (HTN) patients having at least three rounds of distinct treatment options (atl_three_roto) in a 12-month window have elevated risk of next-year complications. However, early identification of these challenge to treat patients is non-trivial and drivers of complications in these vs remaining HTN patients are not fully defined. To address these challenges/gaps, we present predictive models for preceding outcomes, delineate their drivers, and highlight value of their integration for population level risk stratification/management of HTN patients. Materials and Methods 2.47 million HTN patients enrolled through 2015-2016 were selected from a nation-wide commercial claims database. Features associated with their treatment patterns, comedications, and comorbidities were extracted for 2015 and used to model/predict 2016 outcomes of atl_three_roto status and/or HTN complications. Logistic regression-derived odds-ratios were used to delineate drivers of each outcome. Results Prior year treatment patterns, specific hypertension drugs (anti-hypertensives, calcium channel blockers, beta blockers), and congestive heart failure most increased future odds of atl_three_roto status. Regardless of prior year atl_three_roto status, specific comorbidities (renal disease, congestive heart failure, myocardial infarction, vascular disease, diabetes with chronic complications) and comedications (beta blockers, cardiac agents, anti-lipidemics) most increased future odds of HTN complications. Proof-of-concept analysis with an independent dataset demonstrated that integrating these model predictions/drivers thereof can be leveraged for risk stratification/management of HTN patients. Discussion Integrating predictions and their drivers from above models supports early identification and targeted management of at-risk HTN patients. Conclusion We have developed a predictive modeling based approach for risk stratification and management of HTN patients.


Sign in / Sign up

Export Citation Format

Share Document